Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID October 19, 2020 - NASDAQ Companies 0 Bay Street News » View More News for October 19, 2020
